Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,022.87 +5.09 (+0.50%)

Official Closing Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records ↗

September 23, 2025

Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant.

Via Chartmill

Topics Economy

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗

September 22, 2025

Via Stocktwits

Topics Intellectual Property

Unpacking the Latest Options Trading Trends in Eli Lilly ↗

September 22, 2025

Via Benzinga

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Healthcare Sector Outlook: Navigating Regulatory Headwinds and Breakthrough Innovations

September 22, 2025

The healthcare sector is currently experiencing a period of profound transformation, marked by a fascinating dichotomy: groundbreaking medical innovations are driving unprecedented growth for some,...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Via MarketMinute

Topics Economy

NVIDIA's AI Engine Roars On: Data Center Dominance Fuels Stellar Q2, But Market Seeks More

September 22, 2025

NVIDIA (NASDAQ: NVDA) continues to be the undisputed titan in the artificial intelligence arena, recently unveiling a dazzling Q2 fiscal year 2026 earnings report that underscored its foundational role...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month? ↗

September 22, 2025

The drugmaker continues to lead the increasingly competitive market for weight management drugs.

Via The Motley Fool

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

1 ETF to Buy Before the End of 2025 ↗

September 22, 2025

Why buy one growth stock when you can buy more than 300?

Via The Motley Fool

Topics ETFs

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? ↗

September 21, 2025

The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

2 Magnificent S&P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever ↗

September 20, 2025

These two underperforming stocks remain attractive for long-term dividend-seeking investors.

Via The Motley Fool

Topics Economy Stocks

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

Via The Motley Fool

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Via MarketMinute

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy? ↗

September 19, 2025

Eli Lilly's initiative could make the company even more successful than it already is.

Via The Motley Fool

Topics Artificial Intelligence

Where Will Eli Lilly Be in 3 Years? ↗

September 19, 2025

With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.

Via The Motley Fool

Why Shares in Novo Nordisk Soared This Week ↗

September 19, 2025

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.

Via The Motley Fool

Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months ↗

September 19, 2025

Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.

Via The Motley Fool

Topics Bankruptcy

Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything ↗

September 18, 2025

Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold

Via MarketBeat

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Eli Lilly (NY:LLY)

All News about Eli Lilly

Popular Pages